The information within this section of the website is intended for UK Healthcare Professionals. Members of the public, Prostap DCS prescribed patients and UK Practice Managers should follow the relevant links.

Prostap DCS at a glance

Prostap DCS (leuprorelin):

  • is the most widely used LHRH agonist worldwide1, with over 24 million patients treated since 19962
  • benefits from 30 years of experience of leuprorelin3,4
  • has been shown to provide long-term survival for prostate cancer patients, when combined with radiotherapy5
  • has a well-established tolerability: majority of adverse events are related to androgen deprivation; most common events are hot flushes, increased sweating and decreased libido6-9*
  • includes a device which is easy to administer1,2
  • helps protect HCPs from needle stick injuries. Prostap DCS is fitted with a safety device that complies with the latest EU sharps directive and UK legislation8,9,11
  • can be used whenever and LHRH agonist is required for the management of prostate cancer, including neo-adjuvant to radiotherapy5,8,9,12

 

*Men receiving LHRH agonists are at increased risk of developing diabetes and cardiovascular disease. Patients at high risk should appropriately monitored and managed according to current clinical practice. For a full list of adverse events, please refer to the summary of product characteristics.8,9

About Prostap DCS8,9

  • Dual Chamber Syringe (DCS) system delivering leuprorelin8,9

abriefproductoverview-figure1

Therapeutic indications

Prostate cancer8,9

  • Metastatic prostate cancer
  • Locally advanced prostate cancer, as an alternative to surgical castration
  • As an adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer
  • As an adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression
  • As neo-adjuvant treatment prior to radiotherapy in patients with hish-risk localised or locally advanced prostate cancer

Endometriosis8,9

  • Management of endometriosis, including pain relief and reduction of endometriotic lesions
  • Endometrial preparation prior to intrauterine surgical procedures including endometrial ablation or resection
  • Preoperative management of uterine fibroids to reduce their size and associated bleeding

Central precocious puberty

  • Central precocious puberty in girls under 9 years of age and boys under 10 years of age

Administration overview

Intramuscular (IM) or subcutaneous (SC) administration available, depending on indication and dose

abriefproductoverview-figure12

Dosage form

Released from micro particles that are 20µm in diameter

abriefproductoverview-figure13

Needle size

Fine gauge needle

abriefproductoverview-figure14

Image not to scale

Dosing – Prostap SR DCS8

abriefproductoverview-figure15

Dosing – Prostap 3 DCS9

Contact

If you are a healthcare professional and have a query about Prostap DCS, please call Medical Information on:

01628 537 900

If you would like to find out more about how Prostap DCS can help your practice save money, or to order, please call CLARITYpharma on:

0845 080 5190

If you are a healthcare professional and would like to be contacted about Prostap DCS, please enter your details in the short form below

Your Name
Email
Phone
Definition of Role
Practice address
Postcode
*Required fields

Takeda UK Ltd will NOT share any of your details with any other parties. If at any time you wish to unsubscribe from receiving information about Prostap DCS, please call Takeda UK Ltd on 01628 537 900.

References

  1. IMS Midas standard unit sales. (1,000) MAT/JAN/2014.
  2. Takeda UK Ltd. Data on file, DF120604(2).
  3. The Leuprolide Study Group. N Eng J Med 1984;311:1281–1286
  4. Sharifi R, Ratanawong C et al. Advanced Drug Delivery Reviews 1977;28:121–138.
  5. D’Amico A V, Chen M et al. JAMA 2008;299:289–295
  6. Kienle E, Lubben G. Urol Int 1996;56(Suppl 1):23–30.
  7. Tunn U W, Wiedey K. Prostate Cancer Prostatic Dis 2009;12:83–87
  8. Prostap SR DCS. Summary of Product Characteristics.
  9. Prostap 3 DCS. Summary of Product Characteristics.
  10. Takeda UK Ltd. Data on file, UK/DF/1405/0020. Available At http://www.pharmatimes.com/news/takeda_launches_new_prese ntation_of_prostap_980760 Last accessed June 2017
  11. Health and Safety Sharp Instruments in Healthcare Regulations 2013. Available at: http://www.hse.gov.uk/pubns/hsis7.pdf. Last accessed June 2017
  12. National Institute for Health and Care Excellence (NICE). Clinical guideline CG175. Full guideline, 2014.
  13. Abdouelfadel Z & Crawford D. Therapeut Clin Risk Manag 2008;4(2):513–526
  14. Barnes R et al. Study M86-049 Report.
  15. MHRA Prostap® SR DCS UKPAR, 2014. Available at: http://www.mhra.gov.uk/home/groups/par/documents/websiteresources/con120
    442.pdf
    . Last accessed June 2017
  16. Jocham D. Urol Int 1998;60:18–24.
  17. Mottet N et al. European Association of Urology Guidelines on Prostate Cancer, Update March 2016.
  18. D’Amico et al. JAMA 2004;292(7):821–827.
  19. Mottet N et al. Eur Urol 2012;62:213–219.
  20. Wechsel HW et al. Eur Urol 1996;30(Suppl 1):7–14.
  21. Takeda UK Ltd. Data on file. DF121104.
  22. Takeda UK Ltd. Data on file. DF121106.

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for Practice Managers.

If you are not a Practice Manager, please select the appropriate area of this website from the welcome page.

No

I am not a
Practice Manager

Yes

I am a
Practice Manager

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for Healthcare Professionals.

If you are not a Healthcare Professional, please select NO to go back and select the appropriate section of this website for you.

No

I am not a Healthcare Professional

Yes

I am a Healthcare Professional interested in prostate cancer

Yes

I am a Healthcare Professional interested in endometriosis

This part of the Prostap® DCS (leuprorelin acetate) online resource is specifically for patients who have been prescribed Prostap DCS.

If you are not a patient who has been prescribed Prostap DCS, please select the appropriate area of this website from the welcome page.

No

I am not a Prostap DCS prescribed patient.

Yes

I am a Prostap DCS prescribed patient.